News 12.05.2017 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of...
News 26.01.2017 Virometix today announced the appointment of Dr. Pierre A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments Virometix is taking further...
News 16.01.2017 ProteoMediX AG, a diagnostic company producing non-invasive in vitro diagnostic assays for prostate cancer diagnosis, has been awarded ISO 13485:2012 certification. ProteoMediX is proud to announce that it has been awarded ISO 13485:2012 certification for the “Design, development, control of production, and distribution of in vitro diagnostics for prostate cancer”. This...
News 19.12.2016 Schlieren (Zurich), Switzerland, – Kuros Biosciences Ltd. (SIX:KURN) (“Kuros”) today announced the signing of a combination agreement with Xpand Biotechnology B.V. (“Xpand”) with the intention to acquire Xpand by way of an exchange of all Xpand shares for up to 2.105 million new Kuros shares, subject to customary conditions. Xpand...
News 07.12.2016 Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in Schlieren/Zurich, Switzerland. AL-S Pharma will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that...